Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AP-325 in Peripheral Post-surgical Neuropathic Pain
NCT04429919Phase 2Completed
- Sponsor
- Algiax Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of AP-325 in Peripheral neuropathic pain, sponsored by Algiax Pharmaceuticals. Started Jun 2020; status: completed.
02
Drugs
AP-325
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT04429919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429919.